

REMARKS

Amendments to the Specification

The specification has been amended herein to update the Related Applications paragraph and to amend the Brief Description of the Figures to reference the various parts of Figures 1-26. No new matter has been added.

Claim amendments

Claim 25 has been amended herein. Support for this amendment can be found throughout the specification, for example, in Tables 1-3 and in the claims as originally filed. No new matter has been added.

Rejection of Claim 25 Under 35 U.S.C. 102(e)

Claim 25 is rejected under 35 U.S.C. 102(e) as being anticipated by Agrawal et al.

Submitted herewith is a declaration under 37 C.F.R. 1.132 stating that relevant portions of Agrawal et al. cited by the Office Action were derived from the inventor of the instant application and is thus not an invention by “another”. Reconsideration and withdrawal of the rejection are respectfully requested.

Double Patenting

Claim 25 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over Claim 1 of U.S. Patent No. 7,105,495.

Enclosed herewith is a terminal disclaimer executed by Idera Pharmaceuticals, Inc., owner of 100% interest in the instant application

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

Dated: December 27, 2007

Keown & Zuccherro, LLP
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781-938-1805
Facsimile: 781-938-4777

By: /Joseph C. Zuccherro/

Joseph C. Zuccherro
Registration No. 55,762